Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $117.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 50.44% to $117.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $318.3 million through Dec 2025, up 219.3% year-over-year, with the annual reading at $117.8 million for FY2025, 50.44% up from the prior year.
  • Liabilities and Shareholders Equity hit $117.8 million in Q4 2025 for Camp4 Therapeutics, up from $86.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $117.8 million in Q4 2025 to a low of $21.4 million in Q3 2024.
  • Historically, Liabilities and Shareholders Equity has averaged $67.6 million across 3 years, with a median of $62.8 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 42.52% in 2024 and later soared 304.4% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $54.9 million in 2023, then soared by 42.52% to $78.3 million in 2024, then skyrocketed by 50.44% to $117.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CAMP at $117.8 million in Q4 2025, $86.4 million in Q3 2025, and $51.3 million in Q2 2025.